Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

81. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 22 (Suppl 4) September 2016 1 AACE/ACE Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS — 2016 Pauline M. Camacho, MD, FACE; Steven M. Petak, MD, MACE (...) University Osteoporosis and Metabolic Bone Disease Center, Chicago, IL; 2 Associate Clinical Professor Weill-Cornell Medical College, Division Head Endocrinology and Chief of Endocrinology, Houston Methodist Hospital, Houston, TX; 3 School of Medicine and Public Health, University of Wisconsin, Madison, WI; 4 Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN; 5 Clinical Professor of Medicine, University of California, San Francisco; 6 Division of Endocrinology

2016 American Association of Clinical Endocrinologists

82. Osteoporosis and Bone Mineral Density

Osteoporosis and Bone Mineral Density Date of origin: 1998 Last review date: 2016 ACR Appropriateness Criteria ® 1 Osteoporosis and Bone Mineral Density American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Osteoporosis and Bone Mineral Density Variant 1: Asymptomatic BMD screening or individuals with established or clinically suspected low BMD. 1. All women age 65 years and older and men age 70 years and older (asymptomatic screening) 2. Women younger than age 65 (...) years who have additional risk for osteoporosis, based on medical history and other findings. Additional risk factors for osteoporosis include: a. Estrogen deficiency b. A history of maternal hip fracture that occurred after the age of 50 years c. Low body mass ( 1 year before age 42 years) 3. Women younger than age 65 years or men younger than age 70 years who have additional risk factors, including: a. Current use of cigarettes b. Loss of height, thoracic kyphosis 4. Individuals of any age

2016 American College of Radiology

83. Osteoporosis - prevention of fragility fractures

Osteoporosis - prevention of fragility fractures Osteoporosis - prevention of fragility fractures - NICE CKS Share Osteoporosis - prevention of fragility fractures: Summary Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Osteoporosis itself is asymptomatic and often remains undiagnosed until a fragility fracture occurs. An osteoporotic fracture is a fragility (...) fracture occurring as a consequence of increased bone fragility caused by osteoporosis. Characteristically fractures occur in the wrist, spine, and hip. A fragility fracture is defined as a fracture following a fall from standing height or less, although vertebral fractures may occur spontaneously, or as a result of routine activities. In England and Wales, it is estimated that annually around 180,000 fractures occur as a result of osteoporosis. Risk factors for osteoporosis include: Female gender

2016 NICE Clinical Knowledge Summaries

84. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update Full Text available with Trip Pro

Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update Informing evidence‐based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update - Ozel - 2016 - Developmental Medicine & Child Neurology - Wiley Online Library The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

2016 Pediatric Endocrine Society

85. High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women

High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women UTCAT2893, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title High-Protein Diet Without Increased Calcium Intake Can Lead to Ridge Resorption and Osteoporosis in Women Clinical Question How does a high protein diet affect ridge resorption in women? Clinical Bottom Line A high protein diet coupled with a low calcium (...) intake can increase urinary losses of calcium and is linked to osteoporosis and ridge resorption in older women. This is supported by narrative reviews outlining observations of populations who maintain a high protein diet and a narrative review of studies showing the relationship between increased protein intake and increased levels of calcium lost in urine. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence

2015 UTHSCSA Dental School CAT Library

86. Repeat Dual Energy X-Ray Absorptiometry Intervals in Osteoporosis

Repeat Dual Energy X-Ray Absorptiometry Intervals in Osteoporosis Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) in Osteoporosis: Clinical Effectiveness and Guidelines DATE: 04 March 2015 RESEARCH QUESTIONS 1. What are the clinical benefits and harms of repeat dual energy x-ray absorptiometry (DEXA) scans every two years in patients with osteoporosis or at risk for osteoporosis? 2. What are the evidence-based guidelines for DEXA in patients with osteoporosis or at risk for osteoporosis? KEY FINDINGS Two health technology assessments, one observational study, and eight evidence-based guidelines were identified regarding

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

87. Cross-sectional study: An online system shows promise for the early detection of osteoporosis in Asian women

Cross-sectional study: An online system shows promise for the early detection of osteoporosis in Asian women An online system shows promise for the early detection of osteoporosis in Asian women | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here An online system shows promise for the early detection of osteoporosis in Asian women Article Text Adult nursing Cross-sectional study An online system shows promise for the early detection

2015 Evidence-Based Nursing

88. Management of Osteoporosis

Management of Osteoporosis Malaysian Osteoporosis Society Clinical Guidance on Management of Osteoporosis 2 0 12 Academy of Medicine Ministry of Health Malaysia MOH/P/PAK/345.17(GU) Second Edition (2015) 02 Published by: Malaysian Osteoporosis Society c/o No. 79, Jalan SS 23/15 Taman SEA, 47400 Petaling Jaya Selangor Darul Ehsan, Malaysia Endorsed by: Malaysia Health Technology Assessment Section (MaHTAS) Medical Development Division, Ministry of Health Malaysia Level 4, Block E1, Precinct 1 (...) Federal Government Administrative Centre 62590, Putrajaya, Malaysia Copyright The copyright owner of this publication is the Malaysia Osteoporosis Society (persatuan Osteoporosis Malaysia). Content may be reproduced in any number of copies and in any format or medium provided that a copyright acknowledgement to the Malaysia Osteoporosis Society is included and the content is not changed, not sold, nor used to promote or endorse any product or service, and not used in an inappropriate or misleading

2015 Ministry of Health, Malaysia

89. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised edition published June 2020 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2015 SIGN

90. Abaloparatide for postmenopausal osteoporosis ? first and second line

Abaloparatide for postmenopausal osteoporosis ? first and second line Abaloparatide for postmenopausal osteoporosis – first and second line Abaloparatide for postmenopausal osteoporosis – first and second line NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Abaloparatide for postmenopausal osteoporosis – first (...) and second line. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Osteoporosis, Postmenopausal Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Centre, School of Health&Population Sciences, University of Birmingham, Public Health building, Edgbaston, Birmingham, B15 2TT

2014 Health Technology Assessment (HTA) Database.

91. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm

Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm Kim K, Svedbom A, Luo X, Sutradhar S, Kanis JA Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of raloxifene and bazedoxifene for postmenopausal women with osteoporosis, based on their fracture probability, in eight European countries. The authors concluded

2014 NHS Economic Evaluation Database.

92. Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis Full Text available with Trip Pro

Prevalence and clinical prediction of osteoporosis in a contemporary cohort of patients with rheumatoid arthritis Osteoporosis has previously been reported to be twice as common in patients with RA as in controls, but these studies predate the introduction of aggressive management of RA. The aim of this study was to evaluate the prevalence and clinical predictors of osteoporosis in RA in a contemporary cohort and to develop a clinical tool for the identification of patients at risk.The (...) prevalence of osteoporosis was related to clinical and demographic variables in 304 consecutive RA patients undergoing DXA at a single centre between 2009 and 2010 and compared with the frequency of osteoporosis in a population-based cohort of 903 subjects.The RA cohort was predominantly female (81.9%), with an average age of 63.5 years (s.d. 11.8) and a disease duration of 9.6 years (s.d. 10.2). Osteoporosis was present in 91 (29.9%) patients at either the spine or total hip compared with 157/903 (17.4

2014 EvidenceUpdates

93. Denosumab for glucocorticoid-induced osteoporosis

Denosumab for glucocorticoid-induced osteoporosis Denosumab for glucocorticoid-induced osteoporosis Denosumab for glucocorticoid-induced osteoporosis NIHR HSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Denosumab for glucocorticoid-induced osteoporosis. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning (...) Review. 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Diphosphonatess; Osteoporosis Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health&Population Sciences, University of Birmingham, 90 Vincent

2014 Health Technology Assessment (HTA) Database.

94. Osteoporosis Has No Significant Impact On Dental Implant Osseointegration

Osteoporosis Has No Significant Impact On Dental Implant Osseointegration UTCAT2645, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Osteoporosis Has No Significant Impact On Dental Implant Osseointegration Clinical Question Does osteoporosis affect the success rates of osseointegration of dental implants in adult patients? Clinical Bottom Line Adult patient with osteoporosis show no significant increase in dental (...) implant osseointegration failures as compared to adults without osteoporosis. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Chen/2013 1142 human adults Meta-Analysis Key results The meta-analysis reports a lack of impact of osteoporosis on the failures of dental implant. There was a direct influence of a patients osteoporosis on the outcome of dental implants, but it was not significant (n = 4; RR

2014 UTHSCSA Dental School CAT Library

95. FRAX without Bone Mineral Density Versus Osteoporosis Self-Assessment Screening Tool as Predictors of Osteoporosis in Primary Screening of Individuals Aged 70 and Older (Abstract)

FRAX without Bone Mineral Density Versus Osteoporosis Self-Assessment Screening Tool as Predictors of Osteoporosis in Primary Screening of Individuals Aged 70 and Older To compare two well-validated tools--the FRAX without bone mineral density (BMD) and the Osteoporosis Self-Assessment Screening Tool (OST)--in predicting osteoporosis and to define thresholds above and below which it would be reasonable to recommend omitting BMD testing.Retrospective review.General practices in Western (...) Australia.Individuals aged 70 and older responding to a prospective audit of osteoporosis investigation and management for whom dual-energy X-ray absorptiometry scan results and clinical risk factor data were available (N = 626).Receiver operating characteristic (ROC) curves were compared, upper and lower thresholds for omission of screening BMD were proposed, and the statistical performance measures for the tests are reported.The areas under the ROC curves for the OST (0.76-0.82) were slightly better than for FRAX

2014 EvidenceUpdates

96. Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis

Prevalence of osteoporosis in prostate cancer survivors: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2014 DARE.

97. Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women

Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Denosumab versus bifosfonatos para el tratamiento de la osteoporosis en mujeres post menopáusicas [Denosumab versus bisphosphonates for the treatment of osteoporosis in post-menopausal women] Pichon Riviere (...) A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Secco A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Secco A. Denosumab versus bifosfonatos para el tratamiento de la osteoporosis

2014 Health Technology Assessment (HTA) Database.

98. Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines

Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation CADTH. Portable bone mineral density scanners for screening and diagnosis of osteoporosis: uses, limitations, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary of Abstracts. 2013 Authors' conclusions Three non-randomized studies were identified regarding the uses and limitations of portable bone mineral density (BMD) scanners for screening and diagnosis of osteoporosis

2014 Health Technology Assessment (HTA) Database.

99. Osteoporosis in Menopause

Osteoporosis in Menopause Osteoporosis in Menopause - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 36, Issue 9, Pages 839–840 Osteoporosis in Menopause PRINCIPAL AUTHORS, x Aliya Khan , MD Hamilton ON x Michel Fortier , MD Quebec QC x MENOPAUSE AND OSTEOPOROSIS WORKING GROUP x Michel Fortier , MD (Co-Chair) x Michel Fortier , x Robert Reid , MD (Co-Chair) x Robert Reid , x Beth L. Abramson , MD x Beth L. Abramson , x (...) text on ScienceDirect. Abstract Objective To provide guidelines for the health care provider on the prevention, diagnosis, and clinical management of postmenopausal osteoporosis. Outcomes Strategies for identifying and evaluating high-risk individuals, the use of bone mineral density (BMD) and bone turnover markers in assessing diagnosis and response to management, and recommendations regarding nutrition, physical activity, and the selection of pharmacologic therapy to prevent and manage

2014 Society of Obstetricians and Gynaecologists of Canada

100. Sclerostin Inhibition for Osteoporosis - A New Approach. Full Text available with Trip Pro

Sclerostin Inhibition for Osteoporosis - A New Approach. 24382003 2014 02 11 2018 12 03 1533-4406 370 5 2014 Jan 30 The New England journal of medicine N. Engl. J. Med. Sclerostin inhibition for osteoporosis--a new approach. 476-7 10.1056/NEJMe1315500 Becker Carolyn B CB From Brigham and Women's Hospital, Boston. eng Editorial Comment 2014 01 01 United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Bone Density Conservation Agents 3VHF2ZD92J AMG 785 AIM IM N Engl J Med. 2014 (...) Jan 30;370(5):412-20 24382002 Antibodies, Monoclonal administration & dosage Bone Density drug effects Bone Density Conservation Agents administration & dosage Bone Remodeling drug effects Female Humans Osteoporosis, Postmenopausal drug therapy 2014 1 3 6 0 2014 1 3 6 0 2014 2 12 6 0 ppublish 24382003 10.1056/NEJMe1315500

2014 NEJM